Hjem › Crohns sygdom › Alabama
Crohns sygdom kliniske forsøg i Alabama
9 studier for Crohns sygdom søger deltagere på steder i Alabama.
Byer i Alabama
Officiel studietekst (engelsk)
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Digestive Health Specialists /ID# 280827, Dothan
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Gastro Health, Birmingham
- East View Medical Research, Mobile
RekruttererFase 4
Alder 18 til 80 · Alle køn · Opdateret 30. sep. 2026 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Digestive Health Specialists /ID# 266216, Dothan
- East View Medical Research /ID# 270377, Mobile
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 25. sep. 2026 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Digestive Health Specialists of the Southeast, Dothan
- East View Medical Research, Mobile
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07499232Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Digestive Health Specialists, Dothan
RekruttererFase 3
Alder 18 til 70 · Alle køn · Opdateret 24. sep. 2026 · NCT06937099A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Digestive Health Specialsits, Dothan
RekruttererFase 4
Alder 18 til 70 · Alle køn · Opdateret 9. sep. 2026 · NCT06045754A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- University of South Alabama (USA) Physicians Group, Mobile
RekruttererFase 3
Alder 2 og opefter · Alle køn · Opdateret 7. maj 2026 · NCT05442567Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- IMC Gulf Coast Gastroenterology, PC, Fairhope
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 27. apr. 2026 · NCT06456593A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Birmingham
RekruttererFase 2
Alder 18 til 80 · Alle køn · Opdateret 12. mar. 2026 · NCT07113522Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.